KISSEI PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Downward to a Loss

KISSEI PHARMACEUTICAL CO.,LTD. <4547> [TSE Prime] announced its financial results after the market closed on July 29th (15:30). The consolidated ordinary profit for the first quarter of the fiscal year ending March 2026 (April to June) was 2.91 billion yen, a 1.4% increase compared to the same period last year.

However, the full-year forecast for consolidated ordinary profit/loss has been revised downward from an expected profit of 7.40 billion yen to a loss of 2.60 billion yen (compared to a profit of 6.97 billion yen in the previous period), turning to a loss outlook.

At the same time, the April to September period (first half) consolidated ordinary profit/loss has been revised downward from an expected profit of 3.10 billion yen to a loss of 6.90 billion yen (compared to a profit of 2.23 billion yen in the same period of the previous year), turning to a loss outlook.

In the most recent three-month period, from April to June (1Q), the operating profit margin decreased from 10.2% in the same period last year to 9.5%.

Kabutan News